Serina Therapeutics, Inc.

SER Healthcare Biotechnology

Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.

Revenue
+2,500.0%
EPS
+16.7%
Free cash flow
−76.8%

Quarter to June 2026, against a year earlier

1.40 0.25 −15.15%
Market cap
$41.9M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
2/9
Altman Z
−22.07
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
0.00 0.00 6.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
2 1 6 1 1 2 3 2 — —
P/S ratio
107.53 658.37 10.44 623.92 286.49 158.43 39.22 76.66 0.00 0.00
Altman Z-Score
(22.07) (13.44) (4.71) (59.50) (56.11) (40.28) (13.01) 13.19 — —
Altman Z″-Score (non-manufacturers)
(50.64) (35.21) (10.69) (147.67) (141.04) (103.66) (47.87) (22.84) (16.24) (165.44)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — 82.88 (10.44) (5.39) (5.33) (3.06) (2.24) (3.53) —
P/Operating CF
(3.23) (8.03) 272.08 (16.06) (25.05) (35.30) (28.11) (52.31) (54.34) (54.34)
P/B ratio
0.00 72.58 0.00 0.00 0.00 0.00 25.89 13.00 11.65 11.65
EV/Sales
122.88 673.33 9.46 1,138.00 374.11 174.41 38.99 71.86 0.00 0.00
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF
(1.23) (2.20) (10.00) (6.49) (6.84) (8.03) (6.24) (12.51) (7.30) 0.00
Current Ratio
1.71 2.40 5.39 0.24 0.25 0.43 1.23 3.22 5.79 0.03
Net Debt/EBITDA
0.00 0.22 1.53 (2.65) (0.82) (0.40) 0.07 0.63 1.24 0.02
Debt/Equity
(79.62) 0.00 (0.09) (0.61) (0.51) (0.72) 0.58 0.00 0.00 0.00
ROE
858.45% 70.10% (21.24%) 71.68% 100.46% 781.94% (224.08%) (90.66%) 87.15% 191.98%
ROA
(280.54%) (142.00%) 86.31% (327.19%) (245.09%) (191.17%) (134.20%) (73.90%) (102.38%) (241.05%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (437.78%) (461.16%) (441.14%) 0.00%
Return on Tangible Assets
(643.26%) (292.34%) 77.73% 137.21% 128.84% 353.45% (645.46%) (136.33%) (102.65%) 62.68%
Average Days of Receivables
0.00 0.00 0.00 42.94 63.37 329.61 76.68 34.25 27.82 67.48
Earnings Yield
(100.00%) (97.94%) 16.00% (48.36%) (21.76%) (19.10%) (18.70%) (7.28%) (22.51%) (11.81%)
Free Cash Flow Yield
(92.58%) (46.54%) (9.05%) (28.09%) (19.09%) (13.70%) (15.94%) (7.49%) (12.65%) 0.00%
Free Cash Flow per Share
(1.77) (2.33) (1.33) (5.50) (7.30) (7.33) (10.20) (8.08) (7.22) (0.24)
Book value per Share
0.00 0.07 (14.45) (16.05) (11.04) (5.04) 2.47 8.30 9.56 (0.65)
Free Cash Flow
(18.01) (17.16) (2.98) (5.94) (7.85) (7.84) (10.80) (8.02) (6.29) (8.43)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026